The pandemic of diabetes is increasing at an alarming rate worldwide. During pregnancy, there is heightened insulin resistance which leads to gestational diabetes (GD) which can revert to a normal state after delivery or continue as type 2 diabetes later in life. The prevalence of GD in Indian pregnant women has been reported to be very high (16%). GD is associated with several adverse outcomes for both the mother and the fetus. Early detection of GD forms a cornerstone of GD control. To that end, detection of serum or plasma biomarkers early during pregnancy is considered an important first step. However, given the wide array of biomarkers available that have varied accuracy of prediction, a cogent collection of the early markers of GD is still awaited, especially in India. The proposed work aims to bridge this knowledge gap and also provide an estimate of the prevalence of GD in central India. The proposed work will piggyback on the PRIME study, which is currently in the second year and will enroll a total of 3,000 pregnant women this year. Of these, we will enroll 1200-1500 pregnant women who will satisfy the inclusion and exclusion criteria. This study will exploit the enrolment opportunity provided by the PRIME study as well as the infrastructural capacity of the Lata Medical Research Foundation. It is expected that the proposed work will not only provide the research information but will also yield a rational approach to early detection and risk-stratification of pregnant women with regards to GD. The proposed work will also provide later opportunities for exciting genetic, epigenetic and other biomarker studies that are likely to provide interesting and novel insights into the pathogenesis of GD.